Menu
  • Join
  • Login
  • Contact
 

Search abstracts / presentations


Palivizumab treatment of infants at high risk of Respiratory Syncytial Virus (RSV) infections: outcomes of specialty pharmacy services

  • In: G32 - Current issues on drug and healthcare information on Thursday, 6 September 2007, 13:00-15:40
  • At: Beijing (China) (2007)
  • Type: Presentations + Posters
  • By: ADDO-ATUAH, Joyce (University of Tennessee, Memphis, United States of America)
  • Co-author(s): Gourley, Dick (University of Tennessee, Memphis, United States of America)
    Faris, Richard (Nova Factor Incorporated, Memphis, United States of America)
    McKinnon, Barbara (Nova Factor Incorporated, Memphis, United States of America)
    Bush, Andrew J. (University of Tennessee, Memphis, United States of America)
    Gourley, Greta (University of Tennessee, Memphis, United States of America)
  • Abstract:

    Background: The unique characteristics of specialty biopharmaceutical products require special and often product-specific patient services to optimize their therapeutic benefits so as to compensate for their relatively high costs. Objective: To describe the product-specific service model developed by a specialty pharmacy provider for palivizumab

    ..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses